Helen Mackay

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A. Gelmon, Marc Tischkowitz, Helen Mackay et al. · The Lancet Oncology · 2011 · 1.1K citations

Breast Oncology, Medicine, Gynecology +9

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell et al. · Journal of Clinical Oncology · 2020 · 777 citations · Full text

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology · 2014 · 540 citations

Medicine, Randomised Phase 2, Gynecology +6

Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type

Leora Witkowski, Jian Carrot‐Zhang, Steffen Albrecht et al. · Nature Genetics · 2014 · 489 citations

Somatic Smarca4 Mutations, Somatic Variant, Hypercalcemic Type +8

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

Ellen Stelloo, Tjalling Bosse, Remi A. Nout et al. · Modern Pathology · 2015 · 476 citations · Full text

Targetable Pathways, Transportec Initiative, High-risk Endometrial Cancer +10